1
|
Buckle T, Rietbergen DDD, de Wit-van der Veen L, Schottelius M. Lessons learned in application driven imaging agent design for image-guided surgery. Eur J Nucl Med Mol Imaging 2024:10.1007/s00259-024-06791-x. [PMID: 38900308 DOI: 10.1007/s00259-024-06791-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Accepted: 06/04/2024] [Indexed: 06/21/2024]
Abstract
To meet the growing demand for intraoperative molecular imaging, the development of compatible imaging agents plays a crucial role. Given the unique requirements of surgical applications compared to diagnostics and therapy, maximizing translational potential necessitates distinctive imaging agent designs. For effective surgical guidance, exogenous signatures are essential and are achievable through a diverse range of imaging labels such as (radio)isotopes, fluorescent dyes, or combinations thereof. To achieve optimal in vivo utility a balanced molecular design of the tracer as a whole is required, which ensures a harmonious effect of the imaging label with the affinity and specificity (e.g., pharmacokinetics) of a pharmacophore/targeting moiety. This review outlines common design strategies and the effects of refinements in the molecular imaging agent design on the agent's pharmacological profile. This includes the optimization of affinity, pharmacokinetics (including serum binding and target mediated background), biological clearance route, the achievable signal intensity, and the effect of dosing hereon.
Collapse
Affiliation(s)
- Tessa Buckle
- Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, The Netherlands
| | - Daphne D D Rietbergen
- Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, The Netherlands
- Section Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Linda de Wit-van der Veen
- Department of Nuclear Medicine, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Margret Schottelius
- Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine and Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Rue du Bugnon 25A, Agora, Lausanne, CH-1011, Switzerland.
- Agora, pôle de recherche sur le cancer, Lausanne, Switzerland.
| |
Collapse
|
2
|
Machulkin AE, Petrov SA, Bodenko V, Larkina MS, Plotnikov E, Yuldasheva F, Tretyakova M, Bezverkhniaia E, Zyk NY, Stasyuk E, Zelchan R, Majouga AG, Tolmachev V, Orlova A, Beloglazkina EK, Yusubov MS. Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu. ACS Pharmacol Transl Sci 2024; 7:1457-1473. [PMID: 38751647 PMCID: PMC11092120 DOI: 10.1021/acsptsci.4c00070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 04/19/2024] [Accepted: 04/24/2024] [Indexed: 05/18/2024]
Abstract
177Lu-labeled small-molecule prostate-specific membrane antigen (PSMA) targeted tracers are therapeutic agents for metastatic castration-resistant prostate cancer. Optimizing molecular design holds the potential to further enhance the pharmacokinetic properties of PSMA-targeted agents while preserving their potent therapeutic effects. In this study, six novel N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-l-lysine (DCL) urea-based PSMA ligand 2,2',2″,2‴-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid conjugates were synthesized. These conjugates feature polypeptide linkers containing the Phe-Phe peptide sequence and an aromatic fragment at the ε-NH-Lys group of the DCL fragment. The synthesis yielded products with satisfactory yields ranging from 60% to 72%, paving the way for their preclinical evaluation. The labeling of the new variants of urea-based PSMA inhibitors provided a radiochemical yield of over 95%. The 177Lu-labeled conjugates demonstrated specific and moderate affinity binding to PSMA-expressing human cancer cells PC3-pip in vitro and specific accumulation in PSMA-expressing xenografts in vivo. Based on the results, both the lipophilicity and the type of substituent in the linker significantly influence the binding properties of the PSMA inhibitor and its biodistribution profile. Specifically, the studied variants containing a bromine substituent or a hydroxyl group introduced into the aromatic fragment of the phenylalanyl residue in DCL exhibit higher affinities to PSMA compared to variants with only a chlorine-substituted aromatic fragment or variants without any substituents. The [177Lu]Lu-13C with the bromine substituent was characterized by the highest activity accumulation in blood, salivary glands, muscle, bone, and gastrointestinal tract and had inasmuch as an unfavorable pharmacokinetic profile. The negative charge of the carboxyl group in the phenyl moiety of the [177Lu]Lu-13A variant has demonstrated a positive effect on reducing the retention of activity in the liver and the kidneys (the ratio of tumor to kidneys was 1.3-fold). Low accumulation in normal tissues in vivo indicates that this novel PSMA-targeting inhibitor is a promising radioligand.
Collapse
Affiliation(s)
- Aleksei E. Machulkin
- Department
of Chemistry, M.V. Lomonosov Moscow State
University, Leninskie
Gory 1-3, Moscow 119991, Russian Federation
- Department
for Biochemistry, People’s Friendship
University of Russia Named after Patrice Lumumba (RUDN University), Moscow 117198, Russia
| | - Stanislav A. Petrov
- Department
of Chemistry, M.V. Lomonosov Moscow State
University, Leninskie
Gory 1-3, Moscow 119991, Russian Federation
| | - Vitalina Bodenko
- Research
Centrum for Oncotheranostics, Research School of Chemistry and Applied
Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia
- Scientific
and Educational Laboratory of Chemical and Pharmaceutical Research, Siberian State Medical University, Tomsk 634050, Russia
| | - Mariia S. Larkina
- Research
Centrum for Oncotheranostics, Research School of Chemistry and Applied
Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia
- Department
of Pharmaceutical Analysis, Siberian State
Medical University, Tomsk 634050, Russia
| | - Evgenii Plotnikov
- Research
Centrum for Oncotheranostics, Research School of Chemistry and Applied
Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia
- Mental
Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, Russia
| | - Feruza Yuldasheva
- Research
Centrum for Oncotheranostics, Research School of Chemistry and Applied
Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia
| | - Maria Tretyakova
- Research
Centrum for Oncotheranostics, Research School of Chemistry and Applied
Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia
| | - Ekaterina Bezverkhniaia
- Research
Centrum for Oncotheranostics, Research School of Chemistry and Applied
Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia
- Department
of Medicinal Chemistry, Uppsala University, Uppsala 75183, Sweden
| | - Nikolay Yu. Zyk
- Department
of Chemistry, M.V. Lomonosov Moscow State
University, Leninskie
Gory 1-3, Moscow 119991, Russian Federation
| | - Elena Stasyuk
- School of
Nuclear Science and Engineering, Tomsk Polytechnic
University, Tomsk 634050, Russia
| | - Roman Zelchan
- Research
Centrum for Oncotheranostics, Research School of Chemistry and Applied
Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia
| | - Alexander G. Majouga
- Dmitry
Mendeleev University of Chemical Technology of Russia, Miusskaya sq. 9, Moscow 125047, Russian Federation
| | - Vladimir Tolmachev
- Department
of Immunology, Genetics and Pathology, Uppsala
University, Uppsala 75185, Sweden
| | - Anna Orlova
- Department
of Medicinal Chemistry, Uppsala University, Uppsala 75183, Sweden
| | - Elena K. Beloglazkina
- Department
of Chemistry, M.V. Lomonosov Moscow State
University, Leninskie
Gory 1-3, Moscow 119991, Russian Federation
| | - Mekhman S. Yusubov
- Research
Centrum for Oncotheranostics, Research School of Chemistry and Applied
Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia
| |
Collapse
|
3
|
Temml V, Kollár J, Schönleitner T, Höll A, Schuster D, Kutil Z. Combination of In Silico and In Vitro Screening to Identify Novel Glutamate Carboxypeptidase II Inhibitors. J Chem Inf Model 2023; 63:1249-1259. [PMID: 36799916 PMCID: PMC9976286 DOI: 10.1021/acs.jcim.2c01269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Indexed: 02/18/2023]
Abstract
Glutamate carboxypeptidase II (GCPII) is a metalloprotease implicated in neurological diseases and prostate oncology. While several classes of potent GCPII-specific inhibitors exist, the development of novel active scaffolds with different pharmacological profiles remains a challenge. Virtual screening followed by in vitro testing is an effective means for the discovery of novel active compounds. Structure- and ligand-based pharmacophore models were created based on a dataset of known GCPII-selective ligands. These models were used in a virtual screening of the SPECS compound library (∼209.000 compounds). Fifty top-scoring virtual hits were further experimentally tested for their ability to inhibit GCPII enzymatic activity in vitro. Six hits were found to have moderate to high inhibitory potency with the best virtual hit, a modified xanthene, inhibiting GCPII with an IC50 value of 353 ± 24 nM. The identification of this novel inhibitory scaffold illustrates the applicability of pharmacophore-based modeling for the discovery of GCPII-specific inhibitors.
Collapse
Affiliation(s)
- Veronika Temml
- Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria
| | - Jakub Kollár
- Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria
| | - Theresa Schönleitner
- Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria
| | - Anna Höll
- Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria
| | - Daniela Schuster
- Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria
| | - Zsófia Kutil
- Laboratory
of Structural Biology, Institute of Biotechnology
of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252
50 Vestec, Czech
Republic
| |
Collapse
|
4
|
Jedlickova L, Peterkova K, Boateng EM, Ulrychova L, Vacek V, Kutil Z, Jiang Z, Novakova Z, Snajdr I, Kim J, O’Donoghue AJ, Barinka C, Dvorak J. Characterization of glutamate carboxypeptidase 2 orthologs in trematodes. Parasit Vectors 2022; 15:480. [PMID: 36539882 PMCID: PMC9768917 DOI: 10.1186/s13071-022-05556-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 10/19/2022] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Glutamate carboxypeptidase 2 (GCP2) belongs to the M28B metalloprotease subfamily encompassing a variety of zinc-dependent exopeptidases that can be found in many eukaryotes, including unicellular organisms. Limited information exists on the physiological functions of GCP2 orthologs in mammalian tissues outside of the brain and intestine, and such data are completely absent for non-mammalian species. Here, we investigate GCP2 orthologs found in trematodes, not only as putative instrumental molecules for defining their basal function(s) but also as drug targets. METHODS Identified genes encoding M28B proteases Schistosoma mansoni and Fasciola hepatica genomes were analyzed and annotated. Homology modeling was used to create three-dimensional models of SmM28B and FhM28B proteins using published X-ray structures as the template. For S. mansoni, RT-qPCR was used to evaluate gene expression profiles, and, by RNAi, we exploited the possible impact of knockdown on the viability of worms. Enzymes from both parasite species were cloned for recombinant expression. Polyclonal antibodies raised against purified recombinant enzymes and RNA probes were used for localization studies in both parasite species. RESULTS Single genes encoding M28B metalloproteases were identified in the genomes of S. mansoni and F. hepatica. Homology models revealed the conserved three-dimensional fold as well as the organization of the di-zinc active site. Putative peptidase activities of purified recombinant proteins were assayed using peptidic libraries, yet no specific substrate was identified, pointing towards the likely stringent substrate specificity of the enzymes. The orthologs were found to be localized in reproductive, digestive, nervous, and sensory organs as well as parenchymal cells. Knockdown of gene expression by RNAi silencing revealed that the genes studied were non-essential for trematode survival under laboratory conditions, reflecting similar findings for GCP2 KO mice. CONCLUSIONS Our study offers the first insight to our knowledge into M28B protease orthologs found in trematodes. Conservation of their three-dimensional structure, as well as tissue expression pattern, suggests that trematode GCP2 orthologs may have functions similar to their mammalian counterparts and can thus serve as valuable models for future studies aimed at clarifying the physiological role(s) of GCP2 and related subfamily proteases.
Collapse
Affiliation(s)
- Lucie Jedlickova
- grid.15866.3c0000 0001 2238 631XDepartment of Zoology and Fisheries, Center of Infectious Animal Diseases, Faculty of Agrobiology, Food, and Natural Resources, Czech University of Life Sciences, Kamýcká 129, 16521 Prague 6, Czech Republic
| | - Kristyna Peterkova
- grid.15866.3c0000 0001 2238 631XDepartment of Zoology and Fisheries, Center of Infectious Animal Diseases, Faculty of Agrobiology, Food, and Natural Resources, Czech University of Life Sciences, Kamýcká 129, 16521 Prague 6, Czech Republic ,grid.4491.80000 0004 1937 116XDepartment of Parasitology, Faculty of Science, Charles University, Viničná 7, 12844 Prague 2, Czech Republic
| | - Enoch Mensah Boateng
- grid.15866.3c0000 0001 2238 631XDepartment of Zoology and Fisheries, Center of Infectious Animal Diseases, Faculty of Agrobiology, Food, and Natural Resources, Czech University of Life Sciences, Kamýcká 129, 16521 Prague 6, Czech Republic
| | - Lenka Ulrychova
- grid.4491.80000 0004 1937 116XDepartment of Parasitology, Faculty of Science, Charles University, Viničná 7, 12844 Prague 2, Czech Republic ,grid.418095.10000 0001 1015 3316Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Flemingovo N. 2, 16610 Prague 6, Czech Republic
| | - Vojtech Vacek
- grid.15866.3c0000 0001 2238 631XDepartment of Zoology and Fisheries, Center of Infectious Animal Diseases, Faculty of Agrobiology, Food, and Natural Resources, Czech University of Life Sciences, Kamýcká 129, 16521 Prague 6, Czech Republic
| | - Zsofia Kutil
- grid.418095.10000 0001 1015 3316Laboratory of Structural Biology, Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Průmyslová 595, 252 42 Vestec, Czech Republic
| | - Zhenze Jiang
- grid.266100.30000 0001 2107 4242Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093 USA
| | - Zora Novakova
- grid.418095.10000 0001 1015 3316Laboratory of Structural Biology, Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Průmyslová 595, 252 42 Vestec, Czech Republic
| | - Ivan Snajdr
- grid.418095.10000 0001 1015 3316Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Flemingovo N. 2, 16610 Prague 6, Czech Republic
| | - Juan Kim
- grid.15866.3c0000 0001 2238 631XDepartment of Zoology and Fisheries, Center of Infectious Animal Diseases, Faculty of Agrobiology, Food, and Natural Resources, Czech University of Life Sciences, Kamýcká 129, 16521 Prague 6, Czech Republic
| | - Anthony J. O’Donoghue
- grid.266100.30000 0001 2107 4242Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093 USA
| | - Cyril Barinka
- grid.418095.10000 0001 1015 3316Laboratory of Structural Biology, Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Průmyslová 595, 252 42 Vestec, Czech Republic
| | - Jan Dvorak
- grid.15866.3c0000 0001 2238 631XDepartment of Zoology and Fisheries, Center of Infectious Animal Diseases, Faculty of Agrobiology, Food, and Natural Resources, Czech University of Life Sciences, Kamýcká 129, 16521 Prague 6, Czech Republic ,grid.418095.10000 0001 1015 3316Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Flemingovo N. 2, 16610 Prague 6, Czech Republic ,grid.15866.3c0000 0001 2238 631XFaculty of Environmental Sciences, Czech University of Life Sciences, Kamýcká 129, 16521 Prague 6, Czech Republic
| |
Collapse
|
5
|
Krishnan MA, Pandit A, Sharma R, Chelvam V. Imaging of prostate cancer: optimizing affinity to prostate specific membrane antigen by spacer modifications in a tumor spheroid model. J Biomol Struct Dyn 2022; 40:9909-9930. [PMID: 34180367 DOI: 10.1080/07391102.2021.1936642] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Early diagnosis of prostate cancer (PCa) is crucial for staging, treatment and management of patients. Prostate specific membrane antigen (PSMA), highly over-expressed on PCa cells, is an excellent target for selective imaging of PCa. In recent years, various scaffolds have been explored as potential carriers to target diagnostic and therapeutic agents to PSMA+ tumour cells. Numerous fluorescent or radioisotope probes linked via a peptide linker have been developed that selectively binds to PCa cells. However, there are very few reports that examine the effects of chemical modifications in the peptide linker of an imaging probe on its affinity to PSMA protein. This report systematically investigates the impact of hydrophobic aromatic moieties in the peptide linker on PSMA affinity and in vitro performance. For this, a series of fluorescent bioconjugates 12-17 with different aromatic spacers were designed, synthesized, and their interactions within the PSMA pocket were first analysed in silico. Cell uptake studies were then performed for 12-17 in PSMA+ cell lines and 3D tumour models in vitro. Binding affinity values of 12-17 were found to be in the range of 36 to 157.9 nM, and 12 with three aromatic groups in the spacer exhibit highest affinity (KD = 36 nM) compared to 17 which is devoid of aromatic groups. These studies suggest that aromatic groups in the spacer region can significantly affect deep tissue imaging of fluorescent bioconjugates. Bioconjugate 12 can be a promising diagnostic tool, and conjugation to near-infrared agents would further its applications in deep-tissue imaging and surgery. Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Mena Asha Krishnan
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, India
| | - Amit Pandit
- Department of Chemistry, Indian Institute of Technology Indore, Indore, India
| | - Rajesh Sharma
- School of Pharmacy, Devi Ahilya University, Indore, India
| | - Venkatesh Chelvam
- Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, India.,Department of Chemistry, Indian Institute of Technology Indore, Indore, India
| |
Collapse
|
6
|
Chen Y, Minn I, Rowe SP, Lisok A, Chatterjee S, Brummet M, Banerjee SR, Mease RC, Pomper MG. A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents. Biomolecules 2022; 12:biom12030405. [PMID: 35327597 PMCID: PMC8946146 DOI: 10.3390/biom12030405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 02/18/2022] [Accepted: 02/23/2022] [Indexed: 02/01/2023] Open
Abstract
We have synthesized a series of 10 new, PSMA-targeted, near-infrared imaging agents intended for use in vivo for fluorescence-guided surgery (FGS). Compounds were synthesized from the commercially available amine-reactive active NHS ester of DyLight800. We altered the linker between the PSMA-targeting urea moiety and the fluorophore with a view to improve the pharmacokinetics. Chemical yields for the conjugates ranged from 51% to 86%. The Ki values ranged from 0.10 to 2.19 nM. Inclusion of an N-bromobenzyl substituent at the ε-amino group of lysine enhanced PSMA+ PIP tumor uptake, as did hydrophilic substituents within the linker. The presence of a polyethylene glycol chain within the linker markedly decreased renal uptake. In particular, DyLight800-10 demonstrated high specific uptake relative to background signal within kidney, confirmed by immunohistochemistry. These compounds may be useful for FGS in prostate, renal or other PSMA-expressing cancers.
Collapse
|
7
|
Hu Q, Padron K, Hara D, Shi J, Pollack A, Prabhakar R, Tao W. Interactions of Urea-Based Inhibitors with Prostate-Specific Membrane Antigen for Boron Neutron Capture Therapy. ACS OMEGA 2021; 6:33354-33369. [PMID: 34926886 PMCID: PMC8674901 DOI: 10.1021/acsomega.1c03554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 10/04/2021] [Indexed: 06/14/2023]
Abstract
In this study, molecular interactions of prostate-specific membrane antigen (PSMA) with five chemically distinct urea-based boron-containing inhibitors have been investigated at the atomic level using molecular docking and molecular dynamics simulations. The PSMA-inhibitor complexations have been analyzed by comparing their binding modes, secondary structures, root-mean-square deviations, noncovalent interactions, principal components, and binding free energies. PSMA is a cell surface glycoprotein upregulated in cancerous cells and can be targeted by boron-labeled inhibitors for boron neutron capture therapy (BNCT). The effective BNCT requires the selective boron delivery to the tumor area and highly specific PSMA-mediated cellular uptake by tumor. Thus, a potent inhibitor must exhibit both high binding affinity and high boron density. The computational results suggest that the chemical nature of inhibitors affects the binding mode and their association with PSMA is primarily dominated by hydrogen bonding, salt bridge, electrostatic, and π-π interactions. The binding free energies (-28.0, -15.2, -43.9, -23.2, and -38.2 kcal/mol) calculated using λ-dynamics for all inhibitors (In1-5) predict preferential binding that is in accordance with experimental data. Among all inhibitors, In5 was found to be the best candidate for BNCT. The binding of this inhibitor to PSMA preserved its overall secondary structure. These results provide computational insights into the coordination flexibility of PSMA and its interaction with various inhibitors. They can be used for the design and synthesis of efficient BNCT agents with improved drug selectivity and high boron percentage.
Collapse
Affiliation(s)
- Qiaoyu Hu
- Department
of Chemistry, University of Miami, Coral Gables, Florida 33146, United States
| | - Kevin Padron
- Department
of Computer Science, University of Miami, Coral Gables, Florida 33146, United States
| | - Daiki Hara
- Department
of Radiation Oncology, University of Miami
Miller School of Medicine, Miami, Florida 33136, United States
| | - Junwei Shi
- Department
of Radiation Oncology, University of Miami
Miller School of Medicine, Miami, Florida 33136, United States
| | - Alan Pollack
- Department
of Radiation Oncology, University of Miami
Miller School of Medicine, Miami, Florida 33136, United States
| | - Rajeev Prabhakar
- Department
of Chemistry, University of Miami, Coral Gables, Florida 33146, United States
| | - Wensi Tao
- Department
of Radiation Oncology, University of Miami
Miller School of Medicine, Miami, Florida 33136, United States
| |
Collapse
|
8
|
The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody). J Biol Chem 2021; 297:101342. [PMID: 34710374 PMCID: PMC8600089 DOI: 10.1016/j.jbc.2021.101342] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 10/20/2021] [Accepted: 10/20/2021] [Indexed: 11/22/2022] Open
Abstract
Peptide display methods are a powerful tool for discovering new ligands of pharmacologically relevant targets. However, the selected ligands often suffer from low affinity. Using phage display, we identified a new bicyclic peptide binder of prostate-specific membrane antigen (PSMA), a metalloprotease frequently overexpressed in prostate cancer. We show that linking multiple copies of a selected low-affinity peptide to a biocompatible water-soluble N-(2-hydroxypropyl)methacrylamide copolymer carrier (iBody) improved binding of the conjugate by several orders of magnitude. Furthermore, using ELISA, enzyme kinetics, confocal microscopy, and other approaches, we demonstrate that the resulting iBody can distinguish between different conformations of the target protein. The possibility to develop stable, fully synthetic, conformation-selective antibody mimetics has potential applications for molecular recognition, diagnosis and treatment of many pathologies. This strategy could significantly contribute to more effective drug discovery and design.
Collapse
|
9
|
Machulkin AE, Uspenskaya AA, Zyk NY, Nimenko EA, Ber AP, Petrov SA, Shafikov RR, Skvortsov DA, Smirnova GB, Borisova YA, Pokrovsky VS, Kolmogorov VS, Vaneev AN, Ivanenkov YA, Khudyakov AD, Kovalev SV, Erofeev AS, Gorelkin PV, Beloglazkina EK, Zyk NV, Khazanova ES, Majouga AG. PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation. Eur J Med Chem 2021; 227:113936. [PMID: 34717125 DOI: 10.1016/j.ejmech.2021.113936] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 10/17/2021] [Accepted: 10/18/2021] [Indexed: 12/11/2022]
Abstract
Prostate cancer is one of the most commonly diagnosed men's cancers and remains one of the leading causes of cancer death. The development of approaches to the treatment of this oncological disease is an ongoing process. In this work, we have carried out the selection of ligands for the creation of conjugates based on the drug docetaxel and synthesized a series of three docetaxel conjugates. In vitro cytotoxicity of these molecules was evaluated using the MTT assay. Based on the assay results, we selected the conjugate which showed cytotoxic potential close to unmodified docetaxel. At the same time, the molar solubility of the resulting compound increased up to 20 times in comparison with the drug itself. In vivo evaluation on 22Rv1 (PSMA+) xenograft model demonstrated a good potency of the synthesized conjugate to inhibit tumor growth: the inhibition turned out to be more than 80% at a dose of 30 mg/kg. Pharmacokinetic parameters of conjugate distribution were analyzed. Also, it was found that PSMA-targeted docetaxel conjugate is less toxic than docetaxel itself, the decrease of molar acute toxicity in comparison with free docetaxel was up to 20%. Obtained conjugate PSMA-DOC is a good candidate for further expanded preclinical trials because of high antitumor activity, fewer side toxic effects and better solubility.
Collapse
Affiliation(s)
- Aleksei E Machulkin
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation.
| | - Anastasia A Uspenskaya
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Nikolay Y Zyk
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Ekaterina A Nimenko
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Anton P Ber
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Stanislav A Petrov
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Radik R Shafikov
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, GSP-7, Ulitsa Miklukho-Maklaya, 16/10, Moscow, 117997, Russian Federation
| | - Dmitry A Skvortsov
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation; Faculty of Biology and Biotechnologies, Higher School of Economics, Myasnitskaya 13, Moscow, 101000, Russia
| | - Galina B Smirnova
- N.N. Blokhin Cancer Research Center, 24 Kashirskoye Sh., Moscow, 115478, Russia
| | - Yulia A Borisova
- N.N. Blokhin Cancer Research Center, 24 Kashirskoye Sh., Moscow, 115478, Russia
| | - Vadim S Pokrovsky
- N.N. Blokhin Cancer Research Center, 24 Kashirskoye Sh., Moscow, 115478, Russia; RUDN University, Miklukho-Maklaya Str.6, Moscow, 117198, Russian Federation
| | - Vasilii S Kolmogorov
- National University of Science and Technology MISiS, 9 Leninskiy Pr, Moscow, 119049, Russian Federation
| | - Alexander N Vaneev
- National University of Science and Technology MISiS, 9 Leninskiy Pr, Moscow, 119049, Russian Federation
| | - Yan A Ivanenkov
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation; Moscow Institute of Physics and Technology (State University), 9 Institutskiy Lane, Dolgoprudny City, Moscow Region, 141700, Russian Federation; National University of Science and Technology MISiS, 9 Leninskiy Pr, Moscow, 119049, Russian Federation; The Federal State Unitary Enterprise Dukhov Automatics Research Institute, Moscow, 127055, Russia; Institute of Biochemistry and Genetics Ufa Science Centre Russian Academy of Sciences (IBG RAS), Oktyabrya Prospekt 71, Ufa, 450054, Russian Federation
| | - Alexander D Khudyakov
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Sergei V Kovalev
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Alexander S Erofeev
- National University of Science and Technology MISiS, 9 Leninskiy Pr, Moscow, 119049, Russian Federation
| | - Petr V Gorelkin
- National University of Science and Technology MISiS, 9 Leninskiy Pr, Moscow, 119049, Russian Federation
| | - Elena K Beloglazkina
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Nikolay V Zyk
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation
| | - Elena S Khazanova
- LLC Izvarino-Pharma, V. Vnukovskoe, Vnukovskoe Sh., 5th Km., Building 1, Moscow, 108817, Russian Federation
| | - Alexander G Majouga
- Lomonosov Moscow State University, Chemistry Dept., Leninskie Gory, Building 1/3, GSP-1, Moscow, 119991, Russian Federation; National University of Science and Technology MISiS, 9 Leninskiy Pr, Moscow, 119049, Russian Federation; Dmitry Mendeleev University of Chemical Technology of Russia, Miusskaya Sq. 9, Moscow, 125047, Russian Federation
| |
Collapse
|
10
|
Machulkin AE, Shafikov RR, Uspenskaya AA, Petrov SA, Ber AP, Skvortsov DA, Nimenko EA, Zyk NU, Smirnova GB, Pokrovsky VS, Abakumov MA, Saltykova IV, Akhmirov RT, Garanina AS, Polshakov VI, Saveliev OY, Ivanenkov YA, Aladinskaya AV, Finko AV, Yamansarov EU, Krasnovskaya OO, Erofeev AS, Gorelkin PV, Dontsova OA, Beloglazkina EK, Zyk NV, Khazanova ES, Majouga AG. Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them. J Med Chem 2021; 64:4532-4552. [PMID: 33822606 DOI: 10.1021/acs.jmedchem.0c01935] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is a suitable target for specific delivery of antitumor drugs and diagnostic agents due to its overexpression in prostate cancer cells. In the current work, we describe the design, synthesis, and biological evaluation of novel low-molecular PSMA ligands and conjugates with fluorescent dyes FAM-5, SulfoCy5, and SulfoCy7. In vitro evaluation of synthesized PSMA ligands on the activity of PSMA shows that the addition of aromatic amino acids into a linker structure leads to a significant increase in inhibition. The conjugates of the most potent ligand with FAM-5 as well as SulfoCy5 demonstrated high affinities to PSMA-expressing tumor cells in vitro. In vivo biodistribution in 22Rv1 xenografts in Balb/c nude mice of PSMA-SulfoCy5 and PSMA-SulfoCy7 conjugates with a novel PSMA ligand demonstrated good visualization of PSMA-expressing tumors. Also, the conjugate PSMA-SulfoCy7 demonstrated the absence of any explicit toxicity up to 87.9 mg/kg.
Collapse
Affiliation(s)
- Aleksei E Machulkin
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Radik R Shafikov
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation.,Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, GSP-7, Ulitsa Miklukho-Maklaya, 16/10, Moscow 117997, Russian Federation
| | - Anastasia A Uspenskaya
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Stanislav A Petrov
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Anton P Ber
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Dmitry A Skvortsov
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation.,Faculty of Biology and Biotechnologies, Higher School of Economics, Myasnitskaya 13, Moscow 101000, Russia
| | - Ekaterina A Nimenko
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Nikolay U Zyk
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Galina B Smirnova
- N.N. Blokhin Cancer Research Center, 24 Kashirskoye sh., Moscow 115478 , Russia
| | - Vadim S Pokrovsky
- N.N. Blokhin Cancer Research Center, 24 Kashirskoye sh., Moscow 115478 , Russia.,RUDN University, Miklukho-Maklaya str. 6, Moscow 117198, Russian Federation
| | - Maxim A Abakumov
- National University of Science and Technology MISiS, 9 Leninskiy pr., Moscow 119049, Russian Federation
| | - Irina V Saltykova
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Rauf T Akhmirov
- Dmitry Mendeleev University of Chemical Technology of Russia, Miusskaya sq. 9, Moscow 125047, Russian Federation
| | - Anastasiia S Garanina
- National University of Science and Technology MISiS, 9 Leninskiy pr., Moscow 119049, Russian Federation
| | - Vladimir I Polshakov
- Center for Magnetic Tomography and Spectroscopy, Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University, Moscow 119991, Russian Federation
| | - Oleg Y Saveliev
- Center for Magnetic Tomography and Spectroscopy, Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University, Moscow 119991, Russian Federation
| | - Yan A Ivanenkov
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation.,Moscow Institute of Physics and Technology (State University), 9 Institutskiy Lane, Dolgoprudny City, Moscow Region 141700, Russian Federation.,National University of Science and Technology MISiS, 9 Leninskiy pr., Moscow 119049, Russian Federation.,The Federal State Unitary Enterprise Dukhov Automatics Research Institute, Moscow 127055, Russia.,Institute of Biochemistry and Genetics Ufa Science Centre Russian Academy of Sciences (IBG RAS), Oktyabrya Prospekt 71, Ufa 450054, Russian Federation
| | - Anastasiya V Aladinskaya
- Moscow Institute of Physics and Technology (State University), 9 Institutskiy Lane, Dolgoprudny City, Moscow Region 141700, Russian Federation
| | - Alexander V Finko
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Emil U Yamansarov
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Olga O Krasnovskaya
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation.,National University of Science and Technology MISiS, 9 Leninskiy pr., Moscow 119049, Russian Federation
| | - Alexander S Erofeev
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation.,National University of Science and Technology MISiS, 9 Leninskiy pr., Moscow 119049, Russian Federation
| | - Petr V Gorelkin
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation.,National University of Science and Technology MISiS, 9 Leninskiy pr., Moscow 119049, Russian Federation
| | - Olga A Dontsova
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation.,Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, GSP-7, Ulitsa Miklukho-Maklaya, 16/10, Moscow 117997, Russian Federation
| | - Elena K Beloglazkina
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Nikolay V Zyk
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation
| | - Elena S Khazanova
- Izvarino Pharma LLC, v. Vnukovskoe, Vnukovskoe sh., 5th km., Building 1, Moscow 108817, Russian Federation
| | - Alexander G Majouga
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1/3, GSP-1, Moscow 119991, Russian Federation.,National University of Science and Technology MISiS, 9 Leninskiy pr., Moscow 119049, Russian Federation.,Dmitry Mendeleev University of Chemical Technology of Russia, Miusskaya sq. 9, Moscow 125047, Russian Federation
| |
Collapse
|
11
|
Juzeniene A, Stenberg VY, Bruland ØS, Larsen RH. Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2021; 13:779. [PMID: 33668474 PMCID: PMC7918517 DOI: 10.3390/cancers13040779] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 02/07/2021] [Accepted: 02/08/2021] [Indexed: 12/14/2022] Open
Abstract
Bone, lymph node, and visceral metastases are frequent in castrate-resistant prostate cancer patients. Since such patients have only a few months' survival benefit from standard therapies, there is an urgent need for new personalized therapies. The prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a molecular target for imaging diagnostics and targeted radionuclide therapy (theragnostics). PSMA-targeted α therapies (PSMA-TAT) may deliver potent and local radiation more selectively to cancer cells than PSMA-targeted β- therapies. In this review, we summarize both the recent preclinical and clinical advances made in the development of PSMA-TAT, as well as the availability of therapeutic α-emitting radionuclides, the development of small molecules and antibodies targeting PSMA. Lastly, we discuss the potentials, limitations, and future perspectives of PSMA-TAT.
Collapse
Affiliation(s)
- Asta Juzeniene
- Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway;
| | - Vilde Yuli Stenberg
- Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway;
- Nucligen, Ullernchausséen 64, 0379 Oslo, Norway;
- Institute for Clinical Medicine, University of Oslo, Box 1171 Blindern, 0318 Oslo, Norway;
| | - Øyvind Sverre Bruland
- Institute for Clinical Medicine, University of Oslo, Box 1171 Blindern, 0318 Oslo, Norway;
- Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway
| | | |
Collapse
|
12
|
Pastorino S, Riondato M, Uccelli L, Giovacchini G, Giovannini E, Duce V, Ciarmiello A. Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications. Curr Radiopharm 2020; 13:63-79. [PMID: 31362683 PMCID: PMC7509769 DOI: 10.2174/1874471012666190729151540] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 07/15/2019] [Accepted: 07/15/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND The rising incidence rate of prostate cancer (PCa) has promoted the development of new diagnostic and therapeutic radiopharmaceuticals during the last decades. Promising improvements have been achieved in clinical practice using prostate specific membrane antigen (PSMA) labeled agents, including specific antibodies and small molecular weight inhibitors. Focusing on molecular docking studies, this review aims to highlight the progress in the design of PSMA targeted agents for a potential use in nuclear medicine. RESULTS Although the first development of radiopharmaceuticals able to specifically recognize PSMA was exclusively oriented to macromolecule protein structure such as radiolabeled monoclonal antibodies and derivatives, the isolation of the crystal structure of PSMA served as the trigger for the synthesis and the further evaluation of a variety of low molecular weight inhibitors. Among the nuclear imaging probes and radiotherapeutics that have been developed and tested till today, labeled Glutamate-ureido inhibitors are the most prevalent PSMA-targeting agents for nuclear medicine applications. CONCLUSION PSMA represents for researchers the most attractive target for the detection and treatment of patients affected by PCa using nuclear medicine modalities. [99mTc]MIP-1404 is considered the tracer of choice for SPECT imaging and [68Ga]PSMA-11 is the leading diagnostic for PET imaging by general consensus. [18F]DCFPyL and [18F]PSMA-1007 are clearly the emerging PET PSMA candidates for their great potential for a widespread commercial distribution. After paving the way with new imaging tools, academic and industrial R&Ds are now focusing on the development of PSMA inhibitors labeled with alpha or beta minus emitters for a theragnostic application.
Collapse
Affiliation(s)
- Sara Pastorino
- Nuclear Medicine Department, S. Andrea Hospital, Via Vittorio Veneto 197, 19124 La Spezia, Italy
| | - Mattia Riondato
- Nuclear Medicine Department, S. Andrea Hospital, Via Vittorio Veneto 197, 19124 La Spezia, Italy
| | - Licia Uccelli
- Morphology, Surgery and Experimental Medicine Department, University of Ferrara, Via L. Borsari 46, 44121 Ferrara, Italy.,Nuclear Medicine Unit, University Hospital, Via Aldo Moro 8, 44124 Ferrara, Italy
| | - Giampiero Giovacchini
- Nuclear Medicine Department, S. Andrea Hospital, Via Vittorio Veneto 197, 19124 La Spezia, Italy
| | - Elisabetta Giovannini
- Nuclear Medicine Department, S. Andrea Hospital, Via Vittorio Veneto 197, 19124 La Spezia, Italy
| | - Valerio Duce
- Nuclear Medicine Department, S. Andrea Hospital, Via Vittorio Veneto 197, 19124 La Spezia, Italy
| | - Andrea Ciarmiello
- Nuclear Medicine Department, S. Andrea Hospital, Via Vittorio Veneto 197, 19124 La Spezia, Italy
| |
Collapse
|
13
|
Kwon H, Lim H, Ha H, Choi D, Son SH, Nam H, Minn I, Byun Y. Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from α-amino acid with (S)- or (R)-configuration at P1′ region. Bioorg Chem 2020; 104:104304. [DOI: 10.1016/j.bioorg.2020.104304] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 09/15/2020] [Accepted: 09/20/2020] [Indexed: 12/23/2022]
|
14
|
Böhmer VI, Szymanski W, van den Berg K, Mulder C, Kobauri P, Helbert H, van der Born D, Reeβing F, Huizing A, Klopstra M, Samplonius DF, Antunes IF, Sijbesma JWA, Luurtsema G, Helfrich W, Visser TJ, Feringa BL, Elsinga PH. Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation of 18 F-Labeled PSMA-Tracers for Prostate Cancer Imaging. Chemistry 2020; 26:10871-10881. [PMID: 32315486 PMCID: PMC7496508 DOI: 10.1002/chem.202001795] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Indexed: 01/24/2023]
Abstract
Since the seminal contribution of Rolf Huisgen to develop the [3+2] cycloaddition of 1,3-dipolar compounds, its azide-alkyne variant has established itself as the key step in numerous organic syntheses and bioorthogonal processes in materials science and chemical biology. In the present study, the copper(I)-catalyzed azide-alkyne cycloaddition was applied for the development of a modular molecular platform for medical imaging of the prostate-specific membrane antigen (PSMA), using positron emission tomography. This process is shown from molecular design, through synthesis automation and in vitro studies, all the way to pre-clinical in vivo evaluation of fluorine-18- labeled PSMA-targeting 'F-PSMA-MIC' radiotracers (t1/2 =109.7 min). Pre-clinical data indicate that the modular PSMA-scaffold has similar binding affinity and imaging properties to the clinically used [68 Ga]PSMA-11. Furthermore, we demonstrated that targeting the arene-binding in PSMA, facilitated through the [3+2]cycloaddition, can improve binding affinity, which was rationalized by molecular modeling. The here presented PSMA-binding scaffold potentially facilitates easy coupling to other medical imaging moieties, enabling future developments of new modular imaging agents.
Collapse
Affiliation(s)
- Verena I. Böhmer
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Wiktor Szymanski
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Keimpe‐Oeds van den Berg
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Chantal Mulder
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Piermichele Kobauri
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Hugo Helbert
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | | | - Friederike Reeβing
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Anja Huizing
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | | | - Douwe F. Samplonius
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Ines F. Antunes
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Jürgen W. A. Sijbesma
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Gert Luurtsema
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Wijnand Helfrich
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | | | - Ben L. Feringa
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Philip H. Elsinga
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| |
Collapse
|
15
|
Duan X, Liu F, Kwon H, Byun Y, Minn I, Cai X, Zhang J, Pomper MG, Yang Z, Xi Z, Yang X. (S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic Acid as a Novel PSMA Targeting Scaffold for Prostate Cancer Imaging. J Med Chem 2020; 63:3563-3576. [PMID: 32207938 DOI: 10.1021/acs.jmedchem.9b02031] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Xiaojiang Duan
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
| | - Futao Liu
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
| | - Hongmok Kwon
- College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Republic of Korea
| | - Youngjoo Byun
- College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Republic of Korea
| | - Il Minn
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, United States
| | - Xuekang Cai
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
| | - Jingming Zhang
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
| | - Martin G. Pomper
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, United States
| | - Zhi Yang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China
| | - Zhen Xi
- State Key Laboratory of Elemento-Organic Chemistry and Department of Chemical Biology, National Pesticide Engineering Research Center (Tianjin), Nankai University, Tianjin 300071, China
| | - Xing Yang
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
- Institute of Medical Technology, Peking University, Beijing 100191. China
| |
Collapse
|
16
|
Hensbergen A, van Willigen DM, van Beurden F, van Leeuwen PJ, Buckle T, Schottelius M, Maurer T, Wester HJ, van Leeuwen FWB. Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers? Bioconjug Chem 2020; 31:375-395. [PMID: 31855410 PMCID: PMC7033908 DOI: 10.1021/acs.bioconjchem.9b00758] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Revised: 12/19/2019] [Indexed: 12/12/2022]
Abstract
Expressed on virtually all prostate cancers and their metastases, the transmembrane protein prostate-specific membrane antigen (PSMA) provides a valuable target for the imaging of prostate cancer. Not only does PSMA provide a target for noninvasive diagnostic imaging, e.g., PSMA-positron emission tomography (PSMA-PET), it can also be used to guide surgical resections of PSMA-positive lesions. The latter characteristic has led to the development of a plethora of PSMA-targeted tracers, i.e., radiolabeled, fluorescent, or hybrid. With image-guided surgery applications in mind, this review discusses these compounds based on clinical need. Here, the focus is on the chemical aspects (e.g., imaging label, spacer moiety, and targeting vector) and their impact on in vitro and in vivo tracer characteristics (e.g., affinity, tumor uptake, and clearance pattern).
Collapse
Affiliation(s)
- Albertus
Wijnand Hensbergen
- Interventional
Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | - Danny M. van Willigen
- Interventional
Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | - Florian van Beurden
- Interventional
Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- Department
of Urology, Netherlands Cancer Institute-Antoni
van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
| | - Pim J. van Leeuwen
- Department
of Urology, Netherlands Cancer Institute-Antoni
van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
| | - Tessa Buckle
- Interventional
Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- Department
of Urology, Netherlands Cancer Institute-Antoni
van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
| | - Margret Schottelius
- Translational
Radiopharmaceutical Sciences, Department of Nuclear Medicine, Centre
Hospitalier Universitaire Vaudois (CHUV) and Department of Oncology, University of Lausanne (UNIL), 1011 Lausanne, Switzerland
| | - Tobias Maurer
- Department
of Urology and Martini-Klinik, Universitätsklinikum
Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Hans-Jürgen Wester
- Pharmazeutische
Radiochemie, Technische Universität
München, 85748 Garching, Germany
| | - Fijs W. B. van Leeuwen
- Interventional
Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- Department
of Urology, Netherlands Cancer Institute-Antoni
van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
| |
Collapse
|
17
|
Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates. Bioorg Med Chem Lett 2019; 29:2229-2235. [DOI: 10.1016/j.bmcl.2019.06.035] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 06/17/2019] [Accepted: 06/19/2019] [Indexed: 12/17/2022]
|
18
|
Conjugates of Prostate-Specific Membrane Antigen Ligands with Antitumor Drugs. Pharm Chem J 2019. [DOI: 10.1007/s11094-019-01994-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess AP, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG. Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer. J Nucl Med 2019; 61:80-88. [PMID: 31253744 DOI: 10.2967/jnumed.119.229393] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Accepted: 06/18/2019] [Indexed: 12/16/2022] Open
Abstract
Targeted radiopharmaceutical therapy (TRT) using α-particle radiation is a promising approach for treating both large and micrometastatic lesions. We developed prostate-specific membrane antigen (PSMA)-targeted low-molecular-weight agents for 212Pb-based TRT of patients with prostate cancer (PC) by evaluating the matching γ-emitting surrogate, 203Pb. Methods: Five rationally designed low-molecular-weight ligands (L1-L5) were synthesized using the lysine-urea-glutamate scaffold, and PSMA inhibition constants were determined. Tissue biodistribution and SPECT/CT imaging of 203Pb-L1-203Pb-L5 were performed on mice bearing PSMA(+) PC3 PIP and PSMA(-) PC3 flu flank xenografts. The absorbed radiation dose of the corresponding 212Pb-labeled analogs was determined using the biodistribution data. Antitumor efficacy of 212Pb-L2 was evaluated in PSMA(+) PC3 PIP and PSMA(-) PC3 flu tumor models and in the PSMA(+) luciferase-expressing micrometastatic model. 212Pb-L2 was also evaluated for dose-escalated, long-term toxicity. Results: All new ligands were obtained in high yield and purity. PSMA inhibitory activities ranged from 0.10 to 17 nM. 203Pb-L1-203Pb-L5 were synthesized in high radiochemical yield and specific activity. Whole-body clearance of 203Pb-L1-203Pb-L5 was fast. The absorbed dose coefficients (mGy/kBq) of the tumor and kidneys were highest for 203Pb-L5 (31.0, 15.2) and lowest for 203Pb-L2 (8.0, 4.2). The tumor-to-kidney absorbed dose ratio was higher for 203Pb-L3 (3.2) and 203Pb-L4 (3.6) than for the other agents, but with lower tumor-to-blood ratios. PSMA(+) tumor lesions were visualized through SPECT/CT as early as 0.5 h after injection. A proof-of-concept therapy study with a single administration of 212Pb-L2 demonstrated dose-dependent inhibition of tumor growth in the PSMA(+) flank tumor model. 212Pb-L2 also demonstrated an increased survival benefit in the micrometastatic model compared with 177Lu-PSMA-617. Long-term toxicity studies in healthy, immunocompetent CD-1 mice revealed kidney as the dose-limiting organ. Conclusion: 203Pb-L1-203Pb-L5 demonstrated favorable pharmacokinetics for 212Pb-based TRT. The antitumor efficacy of 212Pb-L2 supports the corresponding 203Pb/212Pb theranostic pair for PSMA-based α-particle TRT in advanced PC.
Collapse
Affiliation(s)
- Sangeeta Ray Banerjee
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland .,Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Il Minn
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Vivek Kumar
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Anders Josefsson
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ala Lisok
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Mary Brummet
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Jian Chen
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ana P Kiess
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Cory Brayton
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ronnie C Mease
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - George Sgouros
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Robert F Hobbs
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Martin G Pomper
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.,Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
20
|
Ivanenkov YA, Machulkin AE, Garanina AS, Skvortsov DA, Uspenskaya AA, Deyneka EV, Trofimenko AV, Beloglazkina EK, Zyk NV, Koteliansky VE, Bezrukov DS, Aladinskaya AV, Vorobyeva NS, Puchinina MM, Riabykh GK, Sofronova AA, Malyshev AS, Majouga AG. Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA. Bioorg Med Chem Lett 2019; 29:1246-1255. [DOI: 10.1016/j.bmcl.2019.01.040] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 01/15/2019] [Accepted: 01/30/2019] [Indexed: 12/19/2022]
|
21
|
Šimon P, Knedlík T, Blažková K, Dvořáková P, Březinová A, Kostka L, Šubr V, Konvalinka J, Šácha P. Identification of Protein Targets of Bioactive Small Molecules Using Randomly Photomodified Probes. ACS Chem Biol 2018; 13:3333-3342. [PMID: 30489064 DOI: 10.1021/acschembio.8b00791] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Identifying protein targets of bioactive small molecules often requires complex, lengthy development of affinity probes. We present a method for stochastic modification of small molecules of interest with a photoactivatable phenyldiazirine linker. The resulting isomeric mixture is conjugated to a hydrophilic copolymer decorated with biotin and a fluorophore. We validated this approach using known inhibitors of several medicinally relevant enzymes. At least a portion of the stochastic derivatives retained their binding to the target, enabling target visualization, isolation, and identification. Moreover, the mix of stochastic probes could be separated into fractions and tested for binding affinity. The structure of the active probe could be determined and the probe resynthesized to improve binding efficiency. Our approach can thus enable rapid target isolation, identification, and visualization, while providing information required for subsequent synthesis of an optimized probe.
Collapse
Affiliation(s)
- Petr Šimon
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610, Prague 6, Czech Republic
| | - Tomáš Knedlík
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610, Prague 6, Czech Republic
- Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic
| | - Kristýna Blažková
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610, Prague 6, Czech Republic
- Department of Cell Biology, Faculty of Science, Charles University, Viničná 7, 12843, Prague 2, Czech Republic
| | - Petra Dvořáková
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610, Prague 6, Czech Republic
- Department of Cell Biology, Faculty of Science, Charles University, Viničná 7, 12843, Prague 2, Czech Republic
| | - Anna Březinová
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610, Prague 6, Czech Republic
| | - Libor Kostka
- Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského n. 2, 16206, Prague 6, Czech Republic
| | - Vladimír Šubr
- Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského n. 2, 16206, Prague 6, Czech Republic
| | - Jan Konvalinka
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610, Prague 6, Czech Republic
- Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic
| | - Pavel Šácha
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610, Prague 6, Czech Republic
| |
Collapse
|
22
|
Suvorov NV, Machulkin AE, Ivanova AV, Popkov AM, Bondareva EA, Plotnikova EA, Yakubovskaya RI, Majouga AG, Mironov AF, Grin MA. Synthesis of PSMA-targeted 131- and 152-substituted chlorin e6 derivatives and their biological properties. J PORPHYR PHTHALOCYA 2018. [DOI: 10.1142/s1088424618501006] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Prostate cancer is an extremely common cancer among older men. Conventional chemotherapy has proven to be not effective enough in battling it due to its high systemic toxicity and low selectivity. An alternative method of cancer treatment known as photodynamic therapy (PDT) has been shown to be effective. It is not without its faults either: one of the issues it’s been known to have is the insufficient selectivity of photosensitizer accumulation in tumor tissues. Recent studies, however, seem to indicate that introducing a PSMA-targeted moiety into photosensitizer might prove to be a solution to this problem. The present paper is concerned with synthesis of PSMA-targeted 131- and 152-substituted chlorin e6 conjugates and their biological characteristics. Our data suggests that the developed conjugates show potential as targeted agents for photodynamic therapy.
Collapse
Affiliation(s)
- Nikita V. Suvorov
- MIREA — Russian Technological University, Institute of Fine Chemical Technology, 86, Vernadskogo Avenue, Moscow, 119571, Russian Federation
| | - Alexey E. Machulkin
- Lomonosov Moscow State University, 1, Leninskie Gori, Building 3, Moscow, 119991, Russian Federation
| | - Anna V. Ivanova
- MIREA — Russian Technological University, Institute of Fine Chemical Technology, 86, Vernadskogo Avenue, Moscow, 119571, Russian Federation
| | - Alexander M. Popkov
- MIREA — Russian Technological University, Institute of Fine Chemical Technology, 86, Vernadskogo Avenue, Moscow, 119571, Russian Federation
| | - Elizaveta A. Bondareva
- MIREA — Russian Technological University, Institute of Fine Chemical Technology, 86, Vernadskogo Avenue, Moscow, 119571, Russian Federation
| | - Ekaterina A. Plotnikova
- P. A. Herzen Moscow Oncology Research Institute, 3, 2th Botkinsky Driveway, Moscow, 125284, Russian Federation
| | - Raisa I. Yakubovskaya
- P. A. Herzen Moscow Oncology Research Institute, 3, 2th Botkinsky Driveway, Moscow, 125284, Russian Federation
| | - Alexander G. Majouga
- Dmitry Mendeleev University of Chemical Technology of Russia, 9, Miusskaya Square, Moscow, 125047, Russian Federation
- Lomonosov Moscow State University, 1, Leninskie Gori, Building 3, Moscow, 119991, Russian Federation
| | - Andrey F. Mironov
- MIREA — Russian Technological University, Institute of Fine Chemical Technology, 86, Vernadskogo Avenue, Moscow, 119571, Russian Federation
| | - Mikhail A. Grin
- MIREA — Russian Technological University, Institute of Fine Chemical Technology, 86, Vernadskogo Avenue, Moscow, 119571, Russian Federation
| |
Collapse
|
23
|
Xie F, Cai H, Peng F. Anti-prostate cancer activity of 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazide copper complexes in vivo by bioluminescence imaging. J Biol Inorg Chem 2018; 23:949-956. [PMID: 30006867 PMCID: PMC6330258 DOI: 10.1007/s00775-018-1596-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 07/05/2018] [Indexed: 02/08/2023]
Abstract
Copper 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazide complex (CuHQTS) is a copper complex with strong anticancer activity against cisplatin-resistant neuroblastoma and prostate cancer cells in vitro by cell proliferation assay or fluorescent microscopic imaging. This study aimed to evaluate anti-prostate cancer activity of CuHQTS in vivo by bioluminescence imaging (BLI) and tumor size measurement, using athymic nu/nu mice implanted with prostate cancer cells carrying luciferase reporter gene (Luc-PC3). Growth of Luc-PC3 cells (1 × 105 cells) implanted in athymic nu/nu mice treated with CuHQTS for 2 weeks was suppressed by measurement of luciferase signals (6.18 × 107 to 5.36 × 107 p/s/cm2/sr) with BLI, compared with luciferase signals of Luc-PC3 cells (4.66 × 107 to 1.51 × 108 p/s/cm2/sr, p < 0.05) in the mice treated with normal saline of placebo control. Moreover, the size of PC-3 xenograft tumor (126.5 ± 34.2 mm3) in athymic nu/nu mice treated with CuHQTS was significantly smaller than the size of PC-3 xenograft tumor (218.6 ± 48.0 mm3, p < 0.05) in athymic nu/nu mice treated with normal saline of placebo control, suggesting in vivo tumor growth inhibition activity of CuHQTS on prostate cancer. The findings of this study support further investigation of CuHQTS as a promising new anticancer agent for the treatment of metastatic prostate cancer refractory to anticancer drugs currently available.
Collapse
Affiliation(s)
- Fang Xie
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA
- PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China
| | - Huawei Cai
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China
| | - Fangyu Peng
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
| |
Collapse
|
24
|
Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging 2018; 45:1841-1851. [PMID: 29623376 DOI: 10.1007/s00259-018-4004-5] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Accepted: 03/26/2018] [Indexed: 12/11/2022]
Abstract
PURPOSE Treatment of late-stage prostate cancer by targeted radiotherapeutics such as 131I-MIP-1095 and 177Lu-PSMA-617 has shown encouraging early results. Lu-177 is preferred to I-131 in clinical settings, but targeted radioligand therapy (RLT) with 177Lu-PSMA-617 has not reached its full potential due to insufficient dose delivery to the tumor. We recently developed a dual-targeting radioiodinated ligand, RPS-027, that targets PSMA and uses albumin binding to enable good tumor uptake and significantly reduced kidney uptake in a preclinical model. Further development of this ligand is limited by the inability to independently modify PSMA and albumin binding and the requirement of I-131 for therapeutic application. We therefore sought to devise a new class of trifunctional ligands for RLT with (1) a high-affinity PSMA-binding domain, (2) an albumin-binding group (ABG), and (3) a chelator for radiometals such as 68Ga3+, 177Lu3+ and 225Ac3+. METHODS Ligands incorporating a triazolylphenylurea-containing PSMA-targeting group, an Nε-(2-(4-iodophenyl)acetyl)lysine ABG and the bifunctional chelator p-SCN-Bn-DOTA linked by a PEG-containing polymer containing 0,3,4,6,8 or 12 repeats were prepared. PSMA affinity was determined in LNCaP cells and uptake and tissue distribution was studied in mice bearing LNCaP tumor xenografts and compared to 177Lu-PSMA-617. Imaging studies were performed up to 24 h post-injection (p.i.) using 66Ga3+ and biodistribution studies at 4 h, 24 h and 96 h p.i. with 177Lu3+. RESULTS PSMA affinity was high (IC50 = 1-10 nM) and inversely proportional to the linker length. Tumor uptake correlated with binding affinity and was significantly greater than for 177Lu-PSMA-617 over 96 h. The highest uptake was achieved with 177Lu-RPS-063 (30.0 ± 6.9 %ID/g; 4 h p.i.). Kidney uptake was generally high, with the exception of the lowest affinity ligand 177Lu-RPS-067. Each of the compounds showed slower blood clearance than 177Lu-PSMA-617, with clearance proportional to linker length. CONCLUSIONS The high tumor uptake achieved with these trifunctional ligands predicts larger (up to 4×) doses delivered to the tumor than can be achieved with 177Lu-PSMA-617. Although PSMA-mediated kidney uptake was also observed, the exceptional area under the curve (AUC) in the tumor warrants further investigation of these novel ligands as candidates for RLT.
Collapse
|
25
|
Neburkova J, Sedlak F, Zackova Suchanova J, Kostka L, Sacha P, Subr V, Etrych T, Simon P, Barinkova J, Krystufek R, Spanielova H, Forstova J, Konvalinka J, Cigler P. Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles. Mol Pharm 2018; 15:2932-2945. [PMID: 29389139 DOI: 10.1021/acs.molpharmaceut.7b00889] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Glutamate carboxypeptidase II (GCPII) is a membrane protease overexpressed by prostate cancer cells and detected in the neovasculature of most solid tumors. Targeting GCPII with inhibitor-bearing nanoparticles can enable recognition, imaging, and delivery of treatments to cancer cells. Compared to methods based on antibodies and other large biomolecules, inhibitor-mediated targeting benefits from the low molecular weight of the inhibitor molecules, which are typically stable, easy-to-handle, and able to bind the enzyme with very high affinity. Although GCPII is established as a molecular target, comparing previously reported results is difficult due to the different methodological approaches used. In this work, we investigate the robustness and limitations of GCPII targeting with a diverse range of inhibitor-bearing nanoparticles (various structures, sizes, bionanointerfaces, conjugation chemistry, and surface densities of attached inhibitors). Polymer-coated nanodiamonds, virus-like particles based on bacteriophage Qβ and mouse polyomavirus, and polymeric poly(HPMA) nanoparticles with inhibitors attached by different means were synthesized and characterized. We evaluated their ability to bind GCPII and interact with cancer cells using surface plasmon resonance, inhibition assay, flow cytometry, and confocal microscopy. Regardless of the diversity of the investigated nanosystems, they all strongly interact with GCPII (most with low picomolar Ki values) and effectively target GCPII-expressing cells. The robustness of this approach was limited only by the quality of the nanoparticle bionanointerface, which must be properly designed by adding a sufficient density of hydrophilic protective polymers. We conclude that the targeting of cancer cells overexpressing GCPII is a viable approach transferable to a broad diversity of nanosystems.
Collapse
Affiliation(s)
- Jitka Neburkova
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic.,First Faculty of Medicine , Charles University , Katerinska 32 , 121 08 Prague , Czech Republic
| | - Frantisek Sedlak
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic.,First Faculty of Medicine , Charles University , Katerinska 32 , 121 08 Prague , Czech Republic.,Department of Genetics and Microbiology, Faculty of Science , Charles University , Vinicna 5 , 128 44 Prague 2 , Czech Republic
| | - Jirina Zackova Suchanova
- Department of Genetics and Microbiology, Faculty of Science , Charles University , Vinicna 5 , 128 44 Prague 2 , Czech Republic
| | - Libor Kostka
- Institute of Macromolecular Chemistry of the CAS , Heyrovskeho namesti 2 , 162 06 , Prague 6 , Czech Republic
| | - Pavel Sacha
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic
| | - Vladimir Subr
- Institute of Macromolecular Chemistry of the CAS , Heyrovskeho namesti 2 , 162 06 , Prague 6 , Czech Republic
| | - Tomas Etrych
- Institute of Macromolecular Chemistry of the CAS , Heyrovskeho namesti 2 , 162 06 , Prague 6 , Czech Republic
| | - Petr Simon
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic
| | - Jitka Barinkova
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic
| | - Robin Krystufek
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic
| | - Hana Spanielova
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic.,Department of Genetics and Microbiology, Faculty of Science , Charles University , Vinicna 5 , 128 44 Prague 2 , Czech Republic
| | - Jitka Forstova
- Department of Genetics and Microbiology, Faculty of Science , Charles University , Vinicna 5 , 128 44 Prague 2 , Czech Republic
| | - Jan Konvalinka
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic.,Department of Biochemistry, Faculty of Science , Charles University , Hlavova 2030 , 128 43 Prague 2 , Czech Republic
| | - Petr Cigler
- Institute of Organic Chemistry and Biochemistry of the CAS , Flemingovo namesti 2 , 166 10 Prague , Czech Republic
| |
Collapse
|
26
|
Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J. Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J Nucl Med 2017; 58:17S-26S. [PMID: 28864607 DOI: 10.2967/jnumed.116.186775] [Citation(s) in RCA: 100] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 03/27/2017] [Indexed: 01/19/2023] Open
Abstract
In recent years, several radioligands targeting prostate-specific membrane antigen (PSMA) have been clinically introduced as a new class of theranostic radiopharmaceuticals for the treatment of prostate cancer (PC). In the second decade of the 21st century, a new era in nuclear medicine was initiated by the clinical introduction of small-molecule PSMA inhibitor radioligands, 40 y after the clinical introduction of 18F-FDG. Because of the high incidence and mortality of PC, the new PSMA radioligands have already had a remarkable impact on the clinical management of PC. For the continuing clinical development and long-term success of theranostic agents, designing modern prospective clinical trials in theranostic nuclear medicine is essential. First-in-human studies with PSMA radioligands derived from small-molecule PSMA inhibitors showed highly sensitive imaging of PSMA-positive PC by means of PET and SPECT as well as a dramatic response of metastatic castration-resistant PC after PSMA radioligand therapy. This tremendous success logically led to the initiation of prospective clinical trials with several PSMA radioligands. Meanwhile, MIP-1404, PSMA-11, 2-(3-{1-carboxy-5-[(6-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL), PSMA-617, PSMA-1007, and others have entered or will enter prospective clinical trials soon in several countries. The significance becomes apparent by, for example, the considerable increase in the number of publications about PSMA-targeted PET imaging from 2013 to 2016 (e.g., a search of the Web of Science for "PSMA" AND "PET" found only 19 publications in 2013 but 218 in 2016). Closer examination of the initial success of PC treatment with PSMA inhibitor radiotracers leads to several questions from the basic research perspective as well as from the perspective of clinical demands: What lessons have been learned regarding the design of PSMA radioligands that have already been developed? Has an acceptable compromise between optimal PSMA radioligand design and a broad range of clinical demands been reached? Can the lessons learned from multiple successes within the PSMA experience be transferred to further theranostic approaches?
Collapse
Affiliation(s)
- Klaus Kopka
- Division of Radiopharmaceutical Chemistry, German Cancer Research Center, INF 280, Heidelberg, Germany .,German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Martina Benešová
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.,Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen, Switzerland
| | - Cyril Bařinka
- Laboratory of Structural Biology, Institute of Biotechnology CAS, Prumyslova, Vestec, Czech Republic
| | - Uwe Haberkorn
- Department of Nuclear Medicine, University of Heidelberg, INF 400, Heidelberg, Germany.,Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, INF 280, Heidelberg, Germany; and
| | - John Babich
- Division of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York
| |
Collapse
|
27
|
Knedlík T, Vorlová B, Navrátil V, Tykvart J, Sedlák F, Vaculín Š, Franěk M, Šácha P, Konvalinka J. Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII. FEBS Open Bio 2017; 7:1362-1378. [PMID: 28904865 PMCID: PMC5586342 DOI: 10.1002/2211-5463.12276] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Revised: 06/23/2017] [Accepted: 07/19/2017] [Indexed: 11/09/2022] Open
Abstract
Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate. GCPII expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore, GCPII represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are widely used. However, although mouse GCPII activity has been characterized, a detailed comparison of the enzymatic activity and tissue distribution of the mouse and human GCPII orthologs remains lacking. In this study, we prepared extracellular mouse GCPII and compared it with human GCPII. We found that mouse GCPII possesses lower catalytic efficiency but similar substrate specificity compared with the human protein. Using a panel of GCPII inhibitors, we discovered that inhibition constants are generally similar for mouse and human GCPII. Furthermore, we observed highest expression of GCPII protein in the mouse kidney, brain, and salivary glands. Importantly, we did not detect GCPII in the mouse prostate. Our data suggest that the differences in enzymatic activity and inhibition profile are rather small; therefore, mouse GCPII can approximate human GCPII in drug development and testing. On the other hand, significant differences in GCPII tissue expression must be taken into account when developing novel GCPII-based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism.
Collapse
Affiliation(s)
- Tomáš Knedlík
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic.,Department of Biochemistry Faculty of Science Charles University Prague Czech Republic
| | - Barbora Vorlová
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic.,First Faculty of Medicine Charles University Prague Czech Republic
| | - Václav Navrátil
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic.,Department of Biochemistry Faculty of Science Charles University Prague Czech Republic
| | - Jan Tykvart
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic.,Department of Biochemistry Faculty of Science Charles University Prague Czech Republic.,Present address: Donnelly Centre for Cellular and Biomolecular Research University of Toronto Toronto ON Canada
| | - František Sedlák
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic.,First Faculty of Medicine Charles University Prague Czech Republic.,Department of Genetics and Microbiology Faculty of Science Charles University Prague Czech Republic
| | - Šimon Vaculín
- Department of Normal, Pathological and Clinical Physiology Third Faculty of Medicine Charles University Prague Czech Republic
| | - Miloslav Franěk
- Department of Normal, Pathological and Clinical Physiology Third Faculty of Medicine Charles University Prague Czech Republic
| | - Pavel Šácha
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic
| | - Jan Konvalinka
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic.,Department of Biochemistry Faculty of Science Charles University Prague Czech Republic
| |
Collapse
|
28
|
Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Ponnala S, Babich JW. Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging. Eur J Nucl Med Mol Imaging 2016; 44:647-661. [PMID: 27847991 PMCID: PMC5323493 DOI: 10.1007/s00259-016-3556-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Accepted: 10/19/2016] [Indexed: 01/18/2023]
Abstract
Purpose Current clinical imaging of PSMA-positive prostate cancer by positron emission tomography (PET) mainly features 68Ga-labeled tracers, notably [68Ga]Ga-PSMA-HBED-CC. The longer half-life of fluorine-18 offers significant advantages over Ga-68, clinically and logistically. We aimed to develop high-affinity PSMA inhibitors labeled with fluorine-18 as alternative tracers for prostate cancer. Methods Six triazolylphenyl ureas and their alkyne precursors were synthesized from the Glu-urea-Lys PSMA binding moiety. PSMA affinity was determined in a competitive binding assay using LNCaP cells. The [18F]triazoles were isolated following a Cu(I)-catalyzed click reaction between the alkynes and [18F]fluoroethylazide. The 18F-labeled compounds were evaluated in nude mice bearing LNCaP tumors and compared to [68Ga]Ga-PSMA-HBED-CC and [18F]DCFPyL. Biodistribution studies of the two tracers with the highest imaged-derived tumor uptake and highest PSMA affinity were undertaken at 1 h, 2 h and 4 h post-injection (p.i.), and co-administration of PMPA was used to determine whether uptake was PSMA-specific. Results F-18-labeled triazolylphenyl ureas were prepared with a decay-corrected RCY of 20–40 %, >98 % radiochemical and chemical purity, and specific activity of up to 391 GBq/μmol. PSMA binding (IC50) ranged from 3–36 nM. The position of the triazole influenced tumor uptake (3 > 4 > 2), and direct conjugation of the triazole with the phenylurea moiety was preferred to insertion of a spacer group. Image-derived tumor uptake ranged from 6–14 %ID/g at 2 h p.i., the time of maximum tumor uptake; uptake of [68Ga]Ga-PSMA-HBED-CC and [18F]DCFPyL was 5–6 %ID/g at 1–3 h p.i., the time of maximum tumor uptake. Biodistribution studies of the two most promising compounds gave maximum tumor uptakes of 10.9 ± 1.0 % and 14.3 ± 2.5 %ID/g, respectively, as compared to 6.27 ± 1.44 %ID/g for [68Ga]Ga-PSMA-HBED-CC. Conclusions Six [18F]triazolylphenyl ureas were prepared in good radiochemical yield. Compounds showed PSMA-specific uptake in LNCaP tumors as high as 14 % ID/g, more than a 2-fold increase over [68Ga]Ga-PSMA-HBED-CC. The facile and high-yielding radiosynthesis of these 18F-labeled triazoles as well as their promising in vitro and in vivo characteristics make them worthy of clinical development for PET imaging of prostate cancer. Electronic supplementary material The online version of this article (doi:10.1007/s00259-016-3556-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- James Kelly
- Division of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA
| | - Alejandro Amor-Coarasa
- Division of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA
| | - Anastasia Nikolopoulou
- Division of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA.,Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, 10021, USA
| | - Dohyun Kim
- Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, 10021, USA
| | - Clarence Williams
- Division of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA
| | - Shashikanth Ponnala
- Division of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA
| | - John W Babich
- Division of Radiopharmaceutical Sciences and Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, Belfer Research Building, Room 1600, 413 East 69th Street, New York, NY, 10021, USA. .,Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, 10021, USA. .,Meyer Cancer Center, Weill Cornell Medicine, New York, NY, 10021, USA.
| |
Collapse
|
29
|
Naushad SM, Janaki Ramaiah M, Stanley BA, Prasanna Lakshmi S, Vishnu Priya J, Hussain T, Alrokayan SA, Kutala VK. In silico approaches to identify the potential inhibitors of glutamate carboxypeptidase II (GCPII) for neuroprotection. J Theor Biol 2016; 406:137-42. [DOI: 10.1016/j.jtbi.2016.07.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 07/09/2016] [Accepted: 07/13/2016] [Indexed: 11/30/2022]
|
30
|
Navrátil V, Schimer J, Tykvart J, Knedlík T, Vik V, Majer P, Konvalinka J, Šácha P. DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening. Nucleic Acids Res 2016; 45:e10. [PMID: 27679479 PMCID: PMC5314793 DOI: 10.1093/nar/gkw853] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2016] [Revised: 09/06/2016] [Accepted: 09/15/2016] [Indexed: 12/29/2022] Open
Abstract
Human diseases are often diagnosed by determining levels of relevant enzymes and treated by enzyme inhibitors. We describe an assay suitable for both ultrasensitive enzyme quantification and quantitative inhibitor screening with unpurified enzymes. In the DNA-linked Inhibitor ANtibody Assay (DIANA), the target enzyme is captured by an immobilized antibody, probed with a small-molecule inhibitor attached to a reporter DNA and detected by quantitative PCR. We validate the approach using the putative cancer markers prostate-specific membrane antigen and carbonic anhydrase IX. We show that DIANA has a linear range of up to six logs and it selectively detects zeptomoles of targets in complex biological samples. DIANA's wide dynamic range permits determination of target enzyme inhibition constants using a single inhibitor concentration. DIANA also enables quantitative screening of small-molecule enzyme inhibitors using microliters of human blood serum containing picograms of target enzyme. DIANA's performance characteristics make it a superior tool for disease detection and drug discovery.
Collapse
Affiliation(s)
- Václav Navrátil
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic .,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Jiří Schimer
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Jan Tykvart
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Tomáš Knedlík
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Viktor Vik
- Department of Urology, Thomayer Hospital in Prague, Prague, 140 59, Czech Republic
| | - Pavel Majer
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic
| | - Jan Konvalinka
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic .,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| | - Pavel Šácha
- Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, 166 10, Czech Republic .,Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, 128 43, Czech Republic
| |
Collapse
|
31
|
Navrátil M, Tykvart J, Schimer J, Pachl P, Navrátil V, Rokob TA, Hlouchová K, Rulíšek L, Konvalinka J. Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities. FEBS J 2016; 283:2528-45. [DOI: 10.1111/febs.13761] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 04/25/2016] [Accepted: 05/18/2016] [Indexed: 11/28/2022]
Affiliation(s)
- Michal Navrátil
- Institute of Organic Chemistry and Biochemistry; Gilead Sciences and IOCB Research Centre; Academy of Sciences of the Czech Republic; Prague Czech Republic
- Department of Biochemistry; Faculty of Natural Sciences; Charles University in Prague; Czech Republic
| | - Jan Tykvart
- Institute of Organic Chemistry and Biochemistry; Gilead Sciences and IOCB Research Centre; Academy of Sciences of the Czech Republic; Prague Czech Republic
- Department of Biochemistry; Faculty of Natural Sciences; Charles University in Prague; Czech Republic
| | - Jiří Schimer
- Institute of Organic Chemistry and Biochemistry; Gilead Sciences and IOCB Research Centre; Academy of Sciences of the Czech Republic; Prague Czech Republic
- Department of Biochemistry; Faculty of Natural Sciences; Charles University in Prague; Czech Republic
| | - Petr Pachl
- Institute of Organic Chemistry and Biochemistry; Gilead Sciences and IOCB Research Centre; Academy of Sciences of the Czech Republic; Prague Czech Republic
| | - Václav Navrátil
- Institute of Organic Chemistry and Biochemistry; Gilead Sciences and IOCB Research Centre; Academy of Sciences of the Czech Republic; Prague Czech Republic
- Department of Biochemistry; Faculty of Natural Sciences; Charles University in Prague; Czech Republic
| | - Tibor András Rokob
- Institute of Organic Chemistry; Research Centre for Natural Sciences; Hungarian Academy of Sciences; Budapest Hungary
| | - Klára Hlouchová
- Institute of Organic Chemistry and Biochemistry; Gilead Sciences and IOCB Research Centre; Academy of Sciences of the Czech Republic; Prague Czech Republic
- Department of Biochemistry; Faculty of Natural Sciences; Charles University in Prague; Czech Republic
| | - Lubomír Rulíšek
- Institute of Organic Chemistry and Biochemistry; Gilead Sciences and IOCB Research Centre; Academy of Sciences of the Czech Republic; Prague Czech Republic
| | - Jan Konvalinka
- Institute of Organic Chemistry and Biochemistry; Gilead Sciences and IOCB Research Centre; Academy of Sciences of the Czech Republic; Prague Czech Republic
- Department of Biochemistry; Faculty of Natural Sciences; Charles University in Prague; Czech Republic
| |
Collapse
|
32
|
Machulkin AE, Ivanenkov YA, Aladinskaya AV, Veselov MS, Aladinskiy VA, Beloglazkina EK, Koteliansky VE, Shakhbazyan AG, Sandulenko YB, Majouga AG. Small-molecule PSMA ligands. Current state, SAR and perspectives. J Drug Target 2016; 24:679-93. [DOI: 10.3109/1061186x.2016.1154564] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Alexey E. Machulkin
- Moscow State University, Chemistry Dept, Leninskie Gory, Moscow, Russian Federation
- National University of Science and Technology MISiS, Moscow, Russian Federation
| | - Yan A. Ivanenkov
- Moscow State University, Chemistry Dept, Leninskie Gory, Moscow, Russian Federation
- National University of Science and Technology MISiS, Moscow, Russian Federation
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Anastasia V. Aladinskaya
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Mark S. Veselov
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Vladimir A. Aladinskiy
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | | | - Victor E. Koteliansky
- Moscow State University, Chemistry Dept, Leninskie Gory, Moscow, Russian Federation
- Skolkovo Institute of Science and Technology “Scoltech”, Novaya, Russian Federation
| | - Artem G. Shakhbazyan
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Yuri B. Sandulenko
- Moscow Institute of Physics and Technology (State University), Dolgoprudny City, Russian Federation
| | - Alexander G. Majouga
- Moscow State University, Chemistry Dept, Leninskie Gory, Moscow, Russian Federation
- National University of Science and Technology MISiS, Moscow, Russian Federation
| |
Collapse
|
33
|
Šácha P, Knedlík T, Schimer J, Tykvart J, Parolek J, Navrátil V, Dvořáková P, Sedlák F, Ulbrich K, Strohalm J, Majer P, Šubr V, Konvalinka J. iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201508642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Pavel Šácha
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
- Department of Biochemistry; Faculty of Science; Charles University; Hlavova 8 12843 Prague 2 Czech Republic
| | - Tomáš Knedlík
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
- Department of Biochemistry; Faculty of Science; Charles University; Hlavova 8 12843 Prague 2 Czech Republic
| | - Jiří Schimer
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
- Department of Biochemistry; Faculty of Science; Charles University; Hlavova 8 12843 Prague 2 Czech Republic
| | - Jan Tykvart
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
- Department of Biochemistry; Faculty of Science; Charles University; Hlavova 8 12843 Prague 2 Czech Republic
| | - Jan Parolek
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
- Department of Biochemistry; Faculty of Science; Charles University; Hlavova 8 12843 Prague 2 Czech Republic
| | - Václav Navrátil
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
- Department of Biochemistry; Faculty of Science; Charles University; Hlavova 8 12843 Prague 2 Czech Republic
| | - Petra Dvořáková
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
| | - František Sedlák
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
- First Faculty of Medicine; Charles University; Kateřinská 32 12108 Prague 2 Czech Republic
| | - Karel Ulbrich
- Institute of Macromolecular Chemistry; Academy of Science of the Czech Republic; Heyrovského n. 2 16206 Prague 6 Czech Republic
| | - Jiří Strohalm
- Institute of Macromolecular Chemistry; Academy of Science of the Czech Republic; Heyrovského n. 2 16206 Prague 6 Czech Republic
| | - Pavel Majer
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
| | - Vladimír Šubr
- Institute of Macromolecular Chemistry; Academy of Science of the Czech Republic; Heyrovského n. 2 16206 Prague 6 Czech Republic
| | - Jan Konvalinka
- Institute of Organic Chemistry and Biochemistry; Academy of Science of the Czech Republic; Flemingovo n. 2 16610 Prague 6 Czech Republic
- Department of Biochemistry; Faculty of Science; Charles University; Hlavova 8 12843 Prague 2 Czech Republic
| |
Collapse
|
34
|
Machara A, Konvalinka J, Kotora M. A MODULAR SYNTHESIS OFN-BENZOTRIAZOLE UREAS USING ALKYLATION OF 5-NITROBENZOTRIAZOLE. ChemistrySelect 2016. [DOI: 10.1002/slct.201600025] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Aleš Machara
- Department of Organic Chemistry, Faculty of Science; Charles University in Prague, Hlavova 8; 128 43 Prague 2 Czech Republic
| | - Jan Konvalinka
- Department of Biochemistry, Faculty of Science; Charles University in Prague; Hlavova 8 128 43 Prague 2
- Institute of Organic Chemistry and Biochemistry; Academy of Sciences of the Czech Republic; Flemingovo n.2 166 10 Prague 6 Czech Republic
| | - Martin Kotora
- Department of Organic Chemistry, Faculty of Science; Charles University in Prague, Hlavova 8; 128 43 Prague 2 Czech Republic
| |
Collapse
|
35
|
Šácha P, Knedlík T, Schimer J, Tykvart J, Parolek J, Navrátil V, Dvořáková P, Sedlák F, Ulbrich K, Strohalm J, Majer P, Šubr V, Konvalinka J. iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. Angew Chem Int Ed Engl 2016; 55:2356-60. [PMID: 26749427 PMCID: PMC4755222 DOI: 10.1002/anie.201508642] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Indexed: 11/17/2022]
Abstract
Antibodies are indispensable tools for biomedicine and anticancer therapy. Nevertheless, their use is compromised by high production costs, limited stability, and difficulty of chemical modification. The design and preparation of synthetic polymer conjugates capable of replacing antibodies in biomedical applications such as ELISA, flow cytometry, immunocytochemistry, and immunoprecipitation is reported. The conjugates, named “iBodies”, consist of an HPMA copolymer decorated with low‐molecular‐weight compounds that function as targeting ligands, affinity anchors, and imaging probes. We prepared specific conjugates targeting several proteins with known ligands and used these iBodies for enzyme inhibition, protein isolation, immobilization, quantification, and live‐cell imaging. Our data indicate that this highly modular and versatile polymer system can be used to produce inexpensive and stable antibody substitutes directed toward virtually any protein of interest with a known ligand.
Collapse
Affiliation(s)
- Pavel Šácha
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic
| | - Tomáš Knedlík
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic
| | - Jiří Schimer
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic
| | - Jan Tykvart
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic
| | - Jan Parolek
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic
| | - Václav Navrátil
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic
| | - Petra Dvořáková
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic
| | - František Sedlák
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic.,First Faculty of Medicine, Charles University, Kateřinská 32, 12108, Prague 2, Czech Republic
| | - Karel Ulbrich
- Institute of Macromolecular Chemistry, Academy of Science of the Czech Republic, Heyrovského n. 2, 16206, Prague 6, Czech Republic
| | - Jiří Strohalm
- Institute of Macromolecular Chemistry, Academy of Science of the Czech Republic, Heyrovského n. 2, 16206, Prague 6, Czech Republic
| | - Pavel Majer
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic
| | - Vladimír Šubr
- Institute of Macromolecular Chemistry, Academy of Science of the Czech Republic, Heyrovského n. 2, 16206, Prague 6, Czech Republic.
| | - Jan Konvalinka
- Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 16610, Prague 6, Czech Republic. .,Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12843, Prague 2, Czech Republic.
| |
Collapse
|
36
|
Romero JM, Martin M, Ramirez CL, Dumas VG, Marti MA. Efficient Calculation of Enzyme Reaction Free Energy Profiles Using a Hybrid Differential Relaxation Algorithm: Application to Mycobacterial Zinc Hydrolases. ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY 2015; 100:33-65. [PMID: 26415840 DOI: 10.1016/bs.apcsb.2015.06.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
Determination of the free energy profile for an enzyme reaction mechanism is of primordial relevance, paving the way for our understanding of the enzyme's catalytic power at the molecular level. Although hybrid, mostly DFT-based, QM/MM methods have been extensively applied to this type of studies, achieving accurate and statistically converged results at a moderate computational cost is still an open challenge. Recently, we have shown that accurate results can be achieved in less computational time, combining Jarzynski's relationship with a hybrid differential relaxation algorithm (HyDRA), which allows partial relaxation of the solvent during the nonequilibrium steering of the reaction. In this work, we have applied this strategy to study two mycobacterial zinc hydrolases. Mycobacterium tuberculosis infections are still a worldwide problem and thus characterization and validation of new drug targets is an intense field of research. Among possible drug targets, recently two essential zinc hydrolases, MshB (Rv1170) and MA-amidase (Rv3717), have been proposed and structurally characterized. Although possible mechanisms have been proposed by analogy to the widely studied human Zn hydrolases, several key issues, particularly those related to Zn coordination sphere and its role in catalysis, remained unanswered. Our results show that mycobacterial Zn hydrolases share a basic two-step mechanism. First, the attacking water becomes deprotonated by the conserved base and establishes the new C-O bond leading to a tetrahedral intermediate. The intermediate requires moderate reorganization to allow for proton transfer to the amide N and C-N bond breaking to occur in the second step. Zn ion plays a key role in stabilizing the tetrahedral intermediate and balancing the negative charge of the substrate during hydroxide ion attack. Finally, comparative analysis of other Zn hydrolases points to a convergent mechanistic evolution.
Collapse
Affiliation(s)
- Juan Manuel Romero
- Instituto de Química Física de los Materiales Medio Ambiente y Energía (INQUIMAE), UBA-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina
| | - Mariano Martin
- Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina
| | - Claudia Lilián Ramirez
- Instituto de Química Física de los Materiales Medio Ambiente y Energía (INQUIMAE), UBA-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina
| | - Victoria Gisel Dumas
- Instituto de Química Física de los Materiales Medio Ambiente y Energía (INQUIMAE), UBA-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina; Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina
| | - Marcelo Adrián Marti
- Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina; Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN) CONICET, Ciudad Universitaria, Buenos Aires, Argentina.
| |
Collapse
|
37
|
Tykvart J, Schimer J, Jančařík A, Bařinková J, Navrátil V, Starková J, Šrámková K, Konvalinka J, Majer P, Šácha P. Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II. J Med Chem 2015; 58:4357-63. [PMID: 25923815 DOI: 10.1021/acs.jmedchem.5b00278] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We present here a structure-aided design of inhibitors targeting the active site as well as exosites of glutamate carboxypeptidase II (GCPII), a prostate cancer marker, preparing potent and selective inhibitors that are more than 1000-fold more active toward GCPII than its closest human homologue, glutamate carboxypeptidase III (GCPIII). Additionally, we demonstrate that the prepared inhibitor conjugate can be used for sensitive and selective imaging of GCPII in mammalian cells.
Collapse
Affiliation(s)
- Jan Tykvart
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic.,‡Department of Biochemistry, Faculty of Science, Charles University, Albertov 6, Prague 2, 128 43, Czech Republic
| | - Jiří Schimer
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic.,‡Department of Biochemistry, Faculty of Science, Charles University, Albertov 6, Prague 2, 128 43, Czech Republic
| | - Andrej Jančařík
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic
| | - Jitka Bařinková
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic
| | - Václav Navrátil
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic.,‡Department of Biochemistry, Faculty of Science, Charles University, Albertov 6, Prague 2, 128 43, Czech Republic
| | - Jana Starková
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic
| | - Karolína Šrámková
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic
| | - Jan Konvalinka
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic.,‡Department of Biochemistry, Faculty of Science, Charles University, Albertov 6, Prague 2, 128 43, Czech Republic
| | - Pavel Majer
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic
| | - Pavel Šácha
- †Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, Prague 6, 166 10, Czech Republic.,‡Department of Biochemistry, Faculty of Science, Charles University, Albertov 6, Prague 2, 128 43, Czech Republic
| |
Collapse
|